PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update May 21, 2020 4:00pm EDT
PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device Apr 21, 2020 9:30am EDT
PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update Apr 09, 2020 4:44pm EDT
PAVmed Subsidiary Lucid Diagnostics’ EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award Apr 02, 2020 9:30am EDT
PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing Mar 31, 2020 9:30am EDT
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device Mar 09, 2020 9:30am EDT
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients Mar 02, 2020 9:30am EST
PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett’s Esophagus (BE) Progression Biomarkers Using EsoCheck™ Feb 20, 2020 9:30am EST
